PDF(Pubmed)
Abstract：
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% - 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 - 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine.
摘要：
儿童和青少年在社会中占有很大比例，在COVID-19的传播中起着重要作用。另一方面,他们的教育,精神和身体健康，和安全性受到损害，这使得疫苗接种成为恢复正常生活的关键一步。在当前的系统审查中，在22项已发表研究的50,148名儿童和青少年以及两项正在进行的临床试验的5,279名参与者中,对COVID-19疫苗接种进行了评估.该研究在PROSPERO中注册,ID#CRD42022303615。收集了包括BNT162b2(辉瑞)在内的多种疫苗的数据，mRNA-1273(Moderna),JNJ-78436735（约翰逊和约翰逊），CoronaVac(Sinovac),BBIBP-CorV（国药），腺病毒5型载体疫苗，ZyCov-D,和BBV152(COVAXIN)。此类疫苗的免疫应答和效力在健康儿童和青少年中为96%-100%,并且在患有基础疾病和抑制免疫系统的那些中也是可接受的。目前的系统评价显示，儿童和青少年使用的疫苗具有良好的安全性；然而，如心肌炎和心肌心包炎等不良反应均为一过性，完全消退。因此,为2-21岁的儿童和青少年接种疫苗有利于中止COVID-19大流行。此外，风险收益评估显示，儿童和青少年接种疫苗的结果良好，尤其是那些患有潜在疾病和免疫抑制疾病的人，与成年人一起防止传播，严重感染,负面结果，和新的变体形成。此外，根据荟萃分析，第一次和第二次接种后疫苗的效力和免疫反应分别为91%和92%，分别。同时,所有疫苗的总体免疫应答分别为95%和辉瑞疫苗的91%.
